TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7323709

Group type: EXPERIMENTAL
Intervention: 5 MIU of penicillin intravenously twice daily for 4 days, plus intraincisional injection of penicillin at wound closure
Number of subjects: 222

Group type: COMPARATOR
Intervention: 2 MIU penicillin and 0.5 g streptomycin twice daily for 5 days (control group)
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Penicillin therapy
Number of subjects: 222
Study: 31261928

Group type: EXPERIMENTAL
Intervention: Mixed nuts (250 kcal)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Pretzels (250 kcal)
Number of subjects: 48
Study: 28100626

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 233

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 233
Study: 27484437

Group type: EXPERIMENTAL
Intervention: p-synephrine (S; 100 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: p-synephrine + caffeine (SCF; 100 mg of p-synephrine plus 100 mg of caffeine)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 12
Study: 24960324

Group type: EXPERIMENTAL
Intervention: Casein phosphopeptide amorphous calcium phosphate with fluoride (CPP‐ACPF)
Number of subjects: 1340

Group type: EXPERIMENTAL
Intervention: Sodium fluoride (NaF)
Number of subjects: 1340

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1340

Group type: EXPERIMENTAL
Intervention: CPP‐ACPF
Number of subjects: 1340
Study: 21627458

Group type: EXPERIMENTAL
Intervention: Scaling and root planing
Number of subjects: 60

Group type: COMPARATOR
Intervention: Supragingival cleaning followed by scaling and root planing at 6 months
Number of subjects: 60
Study: 19755410

Group type: EXPERIMENTAL
Intervention: Nateglinide (120 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 17995584

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) with prednisolone for 6 months
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) with prednisolone
Number of subjects: 20

Group type: COMPARATOR
Intervention: Modified Ponticelli regimen (control)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Chlorambucil (compared to MMF)
Number of subjects: 20
Study: 15045183

Group type: EXPERIMENTAL
Intervention: Chronic pelvic pain syndrome
Number of subjects: 770
Study: 11601768

Group type: EXPERIMENTAL
Intervention: Quantec SC rotary instruments
Number of subjects: 20

Group type: COMPARATOR
Intervention: Hand files and solvent
Number of subjects: 20
Study: 9521541

Group type: COMPARATOR
Intervention: Paired association task
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Choice reaction task
Number of subjects: 8
Study: 8078529

Group type: EXPERIMENTAL
Intervention: Budesonide 9 mg daily
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: Budesonide 15 mg daily
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: Budesonide 3 mg daily
Number of subjects: 258

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 258
Study: 2462341

Group type: EXPERIMENTAL
Intervention: Antiarrhythmic drugs (encainide, flecainide, moricizine, imipramine)
Number of subjects: 502

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 502
Study: 55647

Group type: EXPERIMENTAL
Intervention: B.C.G. treatment
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (no B.C.G.)
Number of subjects: 48
Study: 31707805

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 15 mg od plus single antiplatelet therapy (SAPT)
Number of subjects: 2124

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 2.5 mg bid plus dual antiplatelet therapy (DAPT)
Number of subjects: 2124

Group type: COMPARATOR
Intervention: Warfarin plus DAPT
Number of subjects: 2124
Study: 28109423

Group type: EXPERIMENTAL
Intervention: Policy proposals to restrict SNAP benefits based on nutrition quality (e.g., excluding sugary drinks)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Updating the policies regulating SNAP benefits based on nutrition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Activities to restore trust between the public health and anti-hunger communities
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Optional SNAP program that includes both incentives and restrictions
Number of subjects: 0
Study: 25862039

Group type: EXPERIMENTAL
Intervention: Polymyxin B hemoperfusion (PMX HP)
Number of subjects: 243

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 243
Study: 23990895

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) consisting of 12 weekly sessions of either cognitive therapy (n=41) or prolonged exposure (PE, n=49), starting 29.8±5.7 days after ED admission
Number of subjects: 957

Group type: EXPERIMENTAL
Intervention: Delayed Prolonged Exposure (PE) starting at 151.8±42.4 days (n=35)
Number of subjects: 957

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 957
Study: 21831508

Group type: EXPERIMENTAL
Intervention: Metformin (500 mg p.o. three times daily)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: N-acetyl-cysteine (NAC) (600 mg p.o. three times daily)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control (baseline)
Number of subjects: 100
Study: 19772608

Group type: EXPERIMENTAL
Intervention: LMA-Classic
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: LMA-Fastrach
Number of subjects: 0
Study: 18235936

Group type: EXPERIMENTAL
Intervention: Preoperative embolization of the splenic artery
Number of subjects: 27

Group type: COMPARATOR
Intervention: No preoperative embolization (control group)
Number of subjects: 27
Study: 15112975

Group type: EXPERIMENTAL
Intervention: Teicoplanin
Number of subjects: 17

Group type: COMPARATOR
Intervention: Cloxacillin
Number of subjects: 17
Study: 11788129

Group type: EXPERIMENTAL
Intervention: Micronized fenofibrate treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9750032

Group type: EXPERIMENTAL
Intervention: 2 years of daily uracil/tegafur (UFT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 6 cycles of cyclophosphamide/methotrexate/5-fluorouracil (CMF)
Number of subjects: 0
Study: 7882815

Group type: EXPERIMENTAL
Intervention: Chromium picolinate supplementation
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 3284310

Group type: EXPERIMENTAL
Intervention: Mexiletine (MEX)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Quinidine (Q)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Combination therapy (MEX-Q)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Drug free
Number of subjects: 14
Study: 29746993

Group type: EXPERIMENTAL
Intervention: Aerobic exercise plus acupuncture
Number of subjects: 64

Group type: COMPARATOR
Intervention: Acupuncture alone
Number of subjects: 64
Study: 26959668

Group type: EXPERIMENTAL
Intervention: Telephone-based problem-solving treatment (PST)
Number of subjects: 356

Group type: COMPARATOR
Intervention: Education-only (EO)
Number of subjects: 356
Study: 24176498

Group type: EXPERIMENTAL
Intervention: Tritanrix HB+Hib (first dose) and Quinvaxem (second/third doses)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Quinvaxem (three doses)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Tritanrix HB+Hib followed by Quinvaxem
Number of subjects: 400

Group type: COMPARATOR
Intervention: Quinvaxem only
Number of subjects: 400
Study: 22406868

Group type: EXPERIMENTAL
Intervention: Supplementation with retinyl palmitate on the first day postpartum
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control group (not supplemented)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Supplementation with retinyl palmitate
Number of subjects: 96
Study: 20529401

Group type: EXPERIMENTAL
Intervention: MM supplement with improved gruel (MMGG)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Improved gruel only (GG)
Number of subjects: 131
Study: 19001507

Group type: EXPERIMENTAL
Intervention: Esophageal-pressure-guided mechanical ventilation
Number of subjects: 61

Group type: COMPARATOR
Intervention: Standard-of-care mechanical ventilation (control group)
Number of subjects: 61
Study: 16158151

Group type: EXPERIMENTAL
Intervention: Ten Steps to Healthy Feeding intervention
Number of subjects: 500
Study: 12608492

Group type: EXPERIMENTAL
Intervention: Naltrexone 100 mg/day
Number of subjects: 183

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 183
Study: 11083688

Group type: EXPERIMENTAL
Intervention: Long protocol (doubling methacholine concentrations)
Number of subjects: 410

Group type: COMPARATOR
Intervention: Short protocol (fourfold increases in concentration)
Number of subjects: 410
Study: 9276784

Group type: EXPERIMENTAL
Intervention: Adinazolam
Number of subjects: 131

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 131

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 131
Study: 8220399

Group type: EXPERIMENTAL
Intervention: Multivariate nonparametric tests
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Permutation procedure
Number of subjects: 0
Study: 3033751

Group type: EXPERIMENTAL
Intervention: Combined treatment radiotherapy and polychemotherapy (C.A.P. + V.D.S.)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Split‐dose irradiation alone
Number of subjects: 81
Study: 29415891

Group type: EXPERIMENTAL
Intervention: gmDC treatment (23 patients)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: gmDC vaccine (12 acute myeloid leukemia patients)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Standard donor lymphocyte infusion (25 patients)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: gmDC treatment (35 patients total)
Number of subjects: 35
Study: 26721228

Group type: EXPERIMENTAL
Intervention: Volitional preemptive abdominal contraction (VPAC)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Fatigue
Number of subjects: 32

Group type: COMPARATOR
Intervention: Recurrent LBP group
Number of subjects: 32
Study: 25948720

Group type: EXPERIMENTAL
Intervention: Healthiest dietary quintile of modified Alternative Healthy Eating Index
Number of subjects: 27860

Group type: COMPARATOR
Intervention: Lowest dietary quintile of modified Alternative Healthy Eating Index
Number of subjects: 27860
Study: 23589106

Group type: EXPERIMENTAL
Intervention: Vaccination with dendritic cells transduced with wild‐type p53 (Arm B)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Vaccination in combination with MDSC targeted therapy with all‐trans‐retinoic acid (ATRA) (Arm C)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control (Arm A)
Number of subjects: 41
Study: 20608293

Group type: EXPERIMENTAL
Intervention: Rotation-oscillation 'On' (Oral-B Triumph with FlossAction brush head)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Rotation-oscillation 'Off' (used like a manual toothbrush)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Sonic 'On' (Sonicare FlexCare with ProResults standard brush head)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Sonic 'Off' (used like a manual toothbrush)
Number of subjects: 32
Study: 18855824

Group type: EXPERIMENTAL
Intervention: Cocaine self-administration sessions (randomized, placebo-controlled)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Cocaine use
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Abstinence (1 week)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Cocaine use (3 consecutive days)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Abstinence (3 days and 17 days)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Early-night slow-wave activity
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Sufficient early-night slow-wave activity and late night REM sleep
Number of subjects: 12
Study: 16640095

Group type: EXPERIMENTAL
Intervention: salvage regimen associating lopinavir, amprenavir and ritonavir for 26 weeks
Number of subjects: 21
Study: 14675918

Group type: EXPERIMENTAL
Intervention: F/T-PSA ratio <10.7%
Number of subjects: 176

Group type: COMPARATOR
Intervention: F/T-PSA ratio >10.7%
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: High-risk features (T-PSA >10 ng/ml or Gleason sum >=7)
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Low-risk patients with F/T-PSA ratio <10.7%
Number of subjects: 176

Group type: COMPARATOR
Intervention: Low-risk patients with F/T-PSA ratio >10.7%
Number of subjects: 176
Study: 10973768

Group type: EXPERIMENTAL
Intervention: Trimetazidine (40 mg intravenous bolus followed by 60 mg continuous infusion for 48 hours)
Number of subjects: 19725
Study: 8827741

Group type: EXPERIMENTAL
Intervention: Oral midazolam 0.75 mg.kg‐1
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 31524075

Group type: EXPERIMENTAL
Intervention: Prednisolone + AIH
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Prednisolone
Number of subjects: 14
Study: 29654044

Group type: EXPERIMENTAL
Intervention: Low depressive symptoms (PHQ-9 score: 0-4)
Number of subjects: 1742

Group type: EXPERIMENTAL
Intervention: Mild depressive symptoms (PHQ-9 score: 5-9)
Number of subjects: 1742

Group type: EXPERIMENTAL
Intervention: Moderate to severe depressive symptoms (PHQ-9 score: ≥10)
Number of subjects: 1742
Study: 26478277

Group type: EXPERIMENTAL
Intervention: WM training with high PI demands
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: WM training with low PI demands
Number of subjects: 25
Study: 25313065

Group type: EXPERIMENTAL
Intervention: Sulforaphane (50-150 µmol daily for 18 weeks)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 21909698

Group type: EXPERIMENTAL
Intervention: Ethicon™ PROXIMATE™ ILS™
Number of subjects: 529
Study: 18721251

Group type: EXPERIMENTAL
Intervention: Latanoprost given every evening
Number of subjects: 32

Group type: COMPARATOR
Intervention: Pilocarpine/timolol maleate fixed combination (PTFC) given twice daily
Number of subjects: 32
Study: 17133211

Group type: EXPERIMENTAL
Intervention: MK-0518 100 mg
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: MK-0518 200 mg
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: MK-0518 400 mg
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: MK-0518 600 mg
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 12940591

Group type: EXPERIMENTAL
Intervention: Oral conjugated equine estrogen
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Transdermal estradiol replacement
Number of subjects: 24
Study: 10698133

Group type: EXPERIMENTAL
Intervention: Chloral hydrate (75 mg/kg, maximum 2 g)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Midazolam (0.5 mg/kg, maximum 10 mg)
Number of subjects: 40
Study: 9183723

Group type: EXPERIMENTAL
Intervention: Dobutamine (5-40 micrograms/kg/min)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Bicycle exercise (200-400 kg x m/min)
Number of subjects: 25
Study: 8170768

Group type: EXPERIMENTAL
Intervention: Fatiguing maximal isokinetic quadriceps contractions
Number of subjects: 16

Group type: COMPARATOR
Intervention: No exercise (control group)
Number of subjects: 16
Study: 2875317

Group type: EXPERIMENTAL
Intervention: Antihypertensive drug treatment
Number of subjects: 0
Study: 28024882

Group type: EXPERIMENTAL
Intervention: DHA-enriched fish oil (2.4 gr for 8 weeks)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 26744910

Group type: EXPERIMENTAL
Intervention: Teriparatide
Number of subjects: 0
Study: 24091718

Group type: EXPERIMENTAL
Intervention: Depression treatment
Number of subjects: 472
Study: 22241604

Group type: EXPERIMENTAL
Intervention: Injection of laboratory‐expanded, skin‐derived fibroblasts suspended in autologous plasma
Number of subjects: 32

Group type: COMPARATOR
Intervention: Ultrasound-guided injection of local anesthetic and physiotherapy
Number of subjects: 32
Study: 20531220

Group type: EXPERIMENTAL
Intervention: Lamotrigine (dosing ranged from 12.5 to 300 mg/d)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 18662592

Group type: EXPERIMENTAL
Intervention: Palonosetron
Number of subjects: 50

Group type: COMPARATOR
Intervention: Ondansetron
Number of subjects: 50
Study: 16277999

Group type: EXPERIMENTAL
Intervention: Green tea (GT) extract along with a low-energy diet (LED)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Low-energy diet (LED)
Number of subjects: 46
Study: 15328996

Group type: EXPERIMENTAL
Intervention: Ceromer resin veneers
Number of subjects: 72

Group type: COMPARATOR
Intervention: Porcelain veneers
Number of subjects: 72
Study: 11042301

Group type: EXPERIMENTAL
Intervention: Misoprostol (25 micrograms)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 8824694

Group type: EXPERIMENTAL
Intervention: Acute propranolol (0.15 mg kg‐1 i.v.)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Chronic propranolol (80 mg three times daily for 2 weeks)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 1419548

Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dothiepin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lofepramine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mianserin
Number of subjects: 0
Study: 4051686

Group type: EXPERIMENTAL
Intervention: Counseling plus professional psychotherapy
Number of subjects: 110

Group type: COMPARATOR
Intervention: Paraprofessional drug counseling alone
Number of subjects: 110
Study: 29879847

Group type: EXPERIMENTAL
Intervention: Integrated rehabilitation programme (3 weeks inpatient stay and 11 weeks home-based activities)
Number of subjects: 0
Study: 28031053

Group type: EXPERIMENTAL
Intervention: Golimumab 50 mg or 100 mg injections every 4 weeks through week 24
Number of subjects: 356

Group type: COMPARATOR
Intervention: Placebo injections every 4 weeks through week 24
Number of subjects: 356
Study: 25910610

Group type: EXPERIMENTAL
Intervention: High uterosacral vault suspension (HUVS)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Abdominal sacrocolpopexy (SCP)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Both techniques (HUVS and SCP)
Number of subjects: 110
Study: 24199972

Group type: EXPERIMENTAL
Intervention: Valerian/lemon balm
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 21030049

Group type: EXPERIMENTAL
Intervention: Tonsillectomy
Number of subjects: 326

Group type: COMPARATOR
Intervention: Control (surgery unrelated to airway or urinary tract)
Number of subjects: 326
Study: 19117152

Group type: EXPERIMENTAL
Intervention: 8 mg lornoxicam
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 50 mg bupivacaine
Number of subjects: 90

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 90
Study: 16752099

Group type: EXPERIMENTAL
Intervention: Intervention group (family driving sessions)
Number of subjects: 10
Study: 14555269

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) replacement therapy
Number of subjects: 19
Study: 11128843

Group type: EXPERIMENTAL
Intervention: Exercise (groups A + C)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Nonexercising subjects (groups B + D)
Number of subjects: 112
Study: 9201844

Group type: EXPERIMENTAL
Intervention: Premarin, 1 mg/kg intravenously in the immediate postoperative period
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group (no Premarin)
Number of subjects: 64
Study: 1492408

Group type: EXPERIMENTAL
Intervention: Combination of evening primrose oil and fish oil (GLA, EPA, DHA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Magnesium Oxide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 3103406

Group type: EXPERIMENTAL
Intervention: Ketotifen
Number of subjects: 17

Group type: COMPARATOR
Intervention: DSCG
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 17
Study: 30701988

Group type: EXPERIMENTAL
Intervention: Sunitinib (37.5 mg on a continuous daily‐dosing regimen)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study: 26956689

Group type: EXPERIMENTAL
Intervention: Adjuvant XELOX (capecitabine plus oxaliplatin); capecitabine 1000 mg/m2 twice daily on days 1-14, oxaliplatin 130 mg/m2 on day 1 for eight 3-week cycles
Number of subjects: 100
Study: 25952818

Group type: EXPERIMENTAL
Intervention: Platelet-Rich Plasma (PRP) injections
Number of subjects: 192

Group type: COMPARATOR
Intervention: Hyaluronic Acid (HA) injections
Number of subjects: 192
Study: 23250350

Group type: EXPERIMENTAL
Intervention: Minimally invasive surgery with Achillon(®) device
Number of subjects: 47

Group type: COMPARATOR
Intervention: Open surgery with Krackow-type sutures
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 47
Study: 20980493

Group type: EXPERIMENTAL
Intervention: 0.2 mg folic acid/d
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: 0.4 mg folic acid/d
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: 0.8 mg folic acid/d
Number of subjects: 172

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 172
Study: 19118844

Group type: EXPERIMENTAL
Intervention: ERAS program
Number of subjects: 52
Study: 17115351

Group type: EXPERIMENTAL
Intervention: BIAsp 30 plus met
Number of subjects: 255

Group type: COMPARATOR
Intervention: glarg plus glim
Number of subjects: 255
Study: 15646944

Group type: EXPERIMENTAL
Intervention: Flossing in addition to brushing
Number of subjects: 33

Group type: COMPARATOR
Intervention: No flossing (control)
Number of subjects: 33
Study: 11359167

Group type: EXPERIMENTAL
Intervention: Vitamins C and E (1 g ascorbic acid and 600 IU d-alpha-tocopherol daily before diving)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 9236432

Group type: EXPERIMENTAL
Intervention: Perindopril (4 mg/d PO for up to 36 days)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control (no perindopril, n = 7)
Number of subjects: 16
Study: 8179973

Group type: EXPERIMENTAL
Intervention: Cisapride (10 mg four times a day)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Ranitidine (150 mg twice a day)
Number of subjects: 49
Study: 3281529

Group type: EXPERIMENTAL
Intervention: Cold-air exercise
Number of subjects: 20

Group type: COMPARATOR
Intervention: Hot-humid air (sham control)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Methacholine rechallenge
Number of subjects: 20
Study: 29173997

Group type: EXPERIMENTAL
Intervention: Reduced torque (<30Ncm)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Conventional torque (≥30Ncm)
Number of subjects: 18